Pfizer, Sangamo Therapeutics and hemophilia

Sangamo Therapeutics’ stock falls the most in 16 years after Pfizer ends hemophilia pact
Sangamo Therapeutics Inc.’s stock tumbled 56% on Tuesday for its second-biggest one-day percentage decline ever, after Pfizer Inc. terminated a hemophilia A gene-therapy partnership.
Pfizer kills hemophilia gene therapy deal, imperiling Sangamo
Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.
Sangamo shares plunge after Pfizer ends hemophilia A gene therapy deal
Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% in extended trade. Sangamo added that it has now regained the rights to the therapy's development and would explore all options to advance the program,
Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact
Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.
Why did Pfizer's exit from gene therapy program hit Sangamo hard?
Sangamo Therapeutics (SGMO) stock plunged as Pfizer (PFE) ends collaboration on hemophilia A gene therapy. Find out the reasons for the selloff.
Pfizer Ends Sangamo Partnership for Hemophilia Therapy
Sangamo Therapeutics said it will regain rights to develop and commercialize a therapy for hemophilia A after Pfizer terminated their collaboration and license agreement. Sangamo and Pfizer together developed the treatment,
Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership
The biotech company intends to explore ways to move ahead with developing the treatment, including seeking a new collaborator.
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe to severe hemophilia A that it has co-developed with and licensed to Pfizer Inc (NYSE:PFE).
Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal
Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their partnership to co-develop a gene therapy for hemophilia A (HemoA), sending Sangamo’s shares crashing 50% in premarket
Pfizer's 2025 Comeback: What's Driving Growth
Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...
Insider Monkey on MSN35m
Jim Cramer’s Take on Pfizer Inc. (PFE): Bold Predictions for the Future
In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other healthcare stocks Jim ...
Hosted on MSN1d
Pfizer: 4 Reasons to Buy This Stock
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to ...
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Options run thin for Sangamo Therapeutics after Pfizer deal crashes
Abrupt end of Pfizer's hemophilia A gene therapy deal with Sangamo is the latest in a line of flip-flops between the big drug ...
Prediction: This $43 Billion Bet Will Help Pfizer Stock Take Off in 2025.
At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...
Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More.
Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...